An interventional study of Minimally facilitated platform and AI-powered platform in Genetic Predisposition and Family Members, sponsored by Stanford University. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Stanford University · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn whether a new online program developed by the research team is able to help families learn about family cancer risk and how to reduce this risk, as well as help interested family members get low-cost, at-home genetic testing for cancer risk.
The overarching goal of this study is to facilitate cascade genetic testing to reduce the burden of cancer in families with hereditary cancer syndromes (HCS). We will evaluate different versions of a point-of-care cascade genetic testing referral service for probands with recently detected pathogenic or likely pathogenic genetic variants.
242 studies on the registry are indexed under Genetic Predisposition to Disease; 96 are open to participants now.
This study's planned enrollment of 400 is above the median of 238 across 86 interventional studies indexed under Genetic Predisposition to Disease.
Browse Genetic Predisposition to Disease studies →Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria - Probands
Exclusion Criteria - Probands
1. Unable to read and write English or Spanish.
Inclusion Criteria - Relatives
Exclusion Criteria - Relatives
The Minimally Facilitated testing arm is a simplified version of the PROACT-AI platform, that provides participants with access to low-cost testing only, in addition to standard of care.
Other: Minimally facilitated platform
The AI-powered arm will provide participants access to low-cost testing via an AI-powered platform as well as provide additional features including genetic education, motivational interviewing, family communication, and complete follow-up surveys.
Other: AI-powered platform
This group will receive access to low-cost genetic testing via an email link and an access code.
This group will receive access to low-cost genetic testing via an AI-powered platform that will also provide genetic education, motivational interviewing, and family communication
Proportion of all eligible first- and second-degree relatives who undergo genetic testing through Color Health in each study arm
Proportion of all eligible first- and second-degree relatives who undergo genetic testing through Color Health in each study arm
Time frame: 6 months
Proportion of eligible first-degree relatives who undergo genetic testing through Color Health in each study arm
Proportion of eligible first-degree relatives who undergo genetic testing through Color Health in each study arm
Time frame: 6 months
Proportion of index patients for whom at least one eligible relative undergoes genetic testing through Color Health in each study arm
Proportion of index patients for whom at least one eligible relative undergoes genetic testing through Color Health in each study arm
Time frame: 6 months
Proportion of eligible relatives invited by the patient in each study arm
Proportion of eligible relatives invited by the patient in each study arm
Time frame: 180 days
Proportion of eligible relatives who join the PROACT program in each study arm
Proportion of eligible relatives who join the PROACT program in each study arm
Time frame: 28 days
Proportion of relatives who completed the genetic risk education modules as measured by platform paradata [PROACT platform-AI Arm Only]
Proportion of relatives who completed the genetic risk education modules as measured by platform paradata \[PROACT platform-AI Arm Only\]
Time frame: 180 days
Assess Relatives' appraisal of their decision making about genetic testing
Assess Relatives' appraisal of their decision making about genetic testing, as measured by the Decision Quality Scale. The minimum value for the Decision Quality Scale is 7, and the maximum value is 35. A higher score on this scale indicates a better outcome, i.e. a higher score reflects a more positive appraisal of PROACT by relatives regarding their decision-making about genetic testing.
Time frame: 180 days +/- 90 days
Relatives' confidence in their understanding of hereditary cancer risk
To compare enrolled relatives' confidence in their understanding of hereditary cancer risk, using interviews.
Time frame: 180 days +/- 90 days
Compare the proportion of eligible relatives who requested genetic testing in each study arm
Using survey responses, compare the proportion of eligible relatives who requested genetic testing within 6 months of enrollment in each study arm, as measured by survey responses.
Time frame: 6 months
Assess Index patients' appraisal of communication with their relatives
Assess Index patients' appraisal of communication with their relatives, as measured by a modified Patient Assessment of Family Communication Scale. The minimum value of the scale is 10, and the maximum value is 50. A higher score, controlling for baseline, indicates a greater improvement in the patient's assessment of their communication with relatives.
Time frame: 180 days +/- 90 days
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2027; primary completion for Sep 2029, 30 months later.
Of 57 non-industry interventional studies with no phase under Genetic Predisposition to Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 128. This study's planned 30 months is below that.
Counting every sponsor, half of 57 studies reached it within 36 months; a quarter within 18 and three quarters within 128.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: start Jun 2026 → Mar 2027, primary completion Dec 2029 → Sep 2029 and completion Dec 2029 → Sep 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Genetic Predisposition to Disease →